Stroke prevention in non-valvular atrial fibrillation with rivaroxaban.
The new oral anticoagulants are the way of the future when it comes to stroke prevention in atrial fibrillation (AF). The ROCKET-AF trial showed that not only was rivaroxaban non-inferior to warfarin for preventing stroke and systemic embolism, but safer too.